Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › XENE

SILVERARC CAPITAL MANAGEMENT, LLC position in XENE

XENON PHARMACEUTICALS INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 186,821 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$11.3M, representing 1.32% of its reported portfolio and ranking #25 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed XENE holdings in 6 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)186.82K sh
Reported value held$11.28M
Portfolio Weight1.32%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's XENE position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in XENE in Q3 2023 at 53,996 shares (US$1.8M). The position peaked in Q1 2026 at 197,759 shares, worth US$11.5M. Across 6 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 186,821 shares valued at US$11.3M — a reduction of -10,938 shares quarter over quarter.. Notable position changes include a 202% increase in Q4 2023 (shares fell 7% over the following quarter), a 59% trim in Q1 2024 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 54.00K $1.84M New
Q4 2023 163.17K $7.52M Add
Q1 2024 66.09K $2.85M Reduce
Q1 2025 10.12K $339.56K New
Q1 2026 197.76K $11.50M New
Q2 2026 186.82K $11.28M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held XENE?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed XENE holdings in 6 of the last 12 reported quarters, going back to Q3 2023.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in XENE?

As of Q2 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 186.82K shares of XENE (XENON PHARMACEUTICALS INC), valued at $11.28M, representing 1.32% of its reported portfolio and ranking #25.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling XENE?

In the latest 13F filing (Q2 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in XENE. The position peaked in Q1 2026 at 197.76K shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.